Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-042962
Filing Date
2019-11-12
Accepted
2019-11-12 16:31:58
Documents
95
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q akba-10q_20190930.htm 10-Q 3614061
2 EX-10.1 akba-ex101_340.htm EX-10.1 204477
3 EX-10.2 akba-ex102_403.htm EX-10.2 110962
4 EX-10.3 akba-ex103_402.htm EX-10.3 96551
5 EX-10.4 akba-ex104_401.htm EX-10.4 49577
6 EX-31.1 akba-ex311_12.htm EX-31.1 17697
7 EX-31.2 akba-ex312_8.htm EX-31.2 17693
8 EX-32.1 akba-ex321_9.htm EX-32.1 12286
  Complete submission text file 0001564590-19-042962.txt   13958500

Data Files

Seq Description Document Type Size
9 XBRL INSTANCE DOCUMENT akba-20190930.xml EX-101.INS 3143061
10 XBRL TAXONOMY EXTENSION SCHEMA akba-20190930.xsd EX-101.SCH 97268
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE akba-20190930_cal.xml EX-101.CAL 90228
12 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE akba-20190930_def.xml EX-101.DEF 361514
13 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20190930_lab.xml EX-101.LAB 660332
14 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20190930_pre.xml EX-101.PRE 552023
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 191210030
SIC: 2834 Pharmaceutical Preparations